Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S de Bono

Showing results (361-370 of 426) with videos related to

Pageof 43
Sort By:
JAMA Oncology|November 26, 2015
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE TrialNicholas D James, Melissa R Spears, Noel W Clarke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2014
Antitumor activity in RAS-driven tumors by blocking AKT and MEKAnthony W Tolcher, Khurum Khan, Michael Ong, et al.
The Lancet. Oncology|November 12, 2013
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trialJohn C Araujo, Géralyn C Trudel, Fred Saad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2026
Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate CancerDavid D Yang, Aya Abdelnaser, Alexander J Haas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2017
A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid TumorsJoaquin Mateo, Gopinath Ganji, Charlotte Lemech, et al.
Lancet (London, England)|July 11, 2021
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trialChristopher Sweeney, Sergio Bracarda, Cora N Sternberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2018
Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)Jonathan Welti, Adam Sharp, Wei Yuan, et al.
Cancer Research|April 3, 2009
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancerGerhardt Attard, Joost F Swennenhuis, David Olmos, et al.
Cancer Discovery|May 28, 2021
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B TrialSuzanne Carreira, Nuria Porta, Sara Arce-Gallego, et al.
Cancer Research|July 30, 2017
Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer IrradiationYi Yin, Rui Li, Kangling Xu, et al.
Pageof 43

Showing results (361-370 of 426) with videos related to

Sort By:
Pageof 43
JAMA Oncology|November 26, 2015
Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE TrialNicholas D James, Melissa R Spears, Noel W Clarke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2014
Antitumor activity in RAS-driven tumors by blocking AKT and MEKAnthony W Tolcher, Khurum Khan, Michael Ong, et al.
The Lancet. Oncology|November 12, 2013
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trialJohn C Araujo, Géralyn C Trudel, Fred Saad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2026
Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate CancerDavid D Yang, Aya Abdelnaser, Alexander J Haas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2017
A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid TumorsJoaquin Mateo, Gopinath Ganji, Charlotte Lemech, et al.
Lancet (London, England)|July 11, 2021
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trialChristopher Sweeney, Sergio Bracarda, Cora N Sternberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 21, 2018
Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC)Jonathan Welti, Adam Sharp, Wei Yuan, et al.
Cancer Research|April 3, 2009
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancerGerhardt Attard, Joost F Swennenhuis, David Olmos, et al.
Cancer Discovery|May 28, 2021
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B TrialSuzanne Carreira, Nuria Porta, Sara Arce-Gallego, et al.
Cancer Research|July 30, 2017
Androgen Receptor Variants Mediate DNA Repair after Prostate Cancer IrradiationYi Yin, Rui Li, Kangling Xu, et al.
Pageof 43